# Combination of RAD001 and Erlotinib in Patients With Advanced Non Small Cell Lung Cancer Previously Treated Only With Chemotherapy

> **NCT00456833** · PHASE1 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 248 (actual)

## Conditions studied

- Non Small Cell Lung Cancer

## Interventions

- **DRUG:** RAD001
- **DRUG:** erlotinib

## Key facts

- **NCT ID:** NCT00456833
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-06
- **Primary completion:** 2011-03
- **Final completion:** —
- **Target enrollment:** 248 (ACTUAL)
- **Last updated:** 2020-12-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00456833

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00456833, "Combination of RAD001 and Erlotinib in Patients With Advanced Non Small Cell Lung Cancer Previously Treated Only With Chemotherapy". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT00456833. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*